Navigation Links
DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
Date:2/25/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the fourth closing in a private placement consisting of approximately 2.0 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.6 million. The total amount raised in the private placement to date is $9.5 million.

Charles Vista, LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.  The maximum offering in the Private Placement consisted of 9,375,000 units for gross proceeds of $7.5 million.  In addition, the placement agent has been granted an over-allotment option of up to 3,125,000 units to cover over-subscriptions for additional gross proceeds of up to $2.5 million.  The over-allotment option is being exercised in part in connection with this closing.

About DelMar Pharma

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe h
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
2. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
3. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
6. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
7. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals
11. New Avenues to Market - Research Report on Isis Pharmaceuticals, Inc., Avon Products, Inc., Elizabeth Arden, Inc., Boyd Gaming Corporation and Ameristar Casinos, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
(Date:7/29/2014)... 2014 According to a new ... Fixation Devices Market - Global Forecast, Market Share, Size, ... orthopedic trauma fixation devices market is estimated at USD ... at a CAGR of 7.2% from 2014 to 2019, ... in 2020. Browse the Orthopedic Trauma Fixation ...
(Date:7/29/2014)... -- Research and Markets has announced the ... report to their offering. ... a medical device used to provide medication or assist ... cannot achieve adequate oxygen levels to maintain life. Patients ... and ARDS require the need of respiratory devices. The ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Global Respiratory Devices Market 2014-2018 2
... May 19 A meta-analysis of approximately ... The Lancet on May 1, 2010 ... phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated ... in magnitude to that with non-HDL cholesterol or systolic ...
... SAN FRANCISCO , May 19 ... trials evaluating Ferring Pharmaceuticals, LYSTEDA™ (tranexamic acid) tablets, a ... with cyclic heavy menstrual bleeding (HMB), were presented at ... Clinical Meeting in San Francisco , May ...
Cached Medicine Technology:Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 2Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 4Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 5Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 6
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip indicates ... new method was created for any sufferer who is looking ... , The author of the new program, Sarah Summer, says ... actually suffered from yeast infection, too. Actually, this is the ... for this problem. , The Natural Cure for ...
(Date:7/29/2014)... For numerous women from all over the world, finding ... being quite hard. Well, the author of the Make Him ... can help all these women. This is the formula that ... and attention every day. , Daily Gossip reveals in ... Alex Carter who published a unique eBook to detail it. ...
(Date:7/29/2014)... Recent international changes to the ... Nurse Call Systems to be considered medical devices. ... Nurse Call Systems to be clinically regulated, audited ... reduces clinical risks, and is good news for ... and Clinical Risk Committee actively pursuing corporate governance. ...
(Date:7/29/2014)... Daily Gossip reveals in its review that the Tinnitus Miracle ... eliminate all the symptoms associated to this condition. , ... such as mild hearing loss, as well as headaches. The ... gone forever. , The method will lead to a cure ... says that at the end of the treatment, sufferers will ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... ,Using the male chromosome as a marker, researchers studying ... have discovered that the body can actively reshape the ... that the heart cannot repair itself and the finding ... realization that the body works to repair a damaged ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... say they have discovered molecules in the body ... free radicals.With further research, the research could potentially ... Oxidative damage has been linked with ailments such ... and diabetes, cancer and Alzheimer’s disease. ...
... a steroid nasal spray may relieve seasonal ... Dr. Robert Naclerio and colleagues from University ... nasal spray, with loratadine(Claritin),a nonsedating antihistamine, for ... , Participants who used the inhaled ...
... way to slow down the respiration rate. Just by practising ... can be slowed down and thereby calm the heart rhythm. ... ritual in the Catholic Church - and the benefits may ... Cleavland, recorded breathing rates during normal talking and recitation of ...
... from asthma, particularly women, may have an increased risk ... years, researchers studied almost 100,000 patients who had been ... showed any signs of cancer at their initial assessment. ... asthma diagnosis until the last day of the three-decade ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: